RSV vaccines

RSV vaccines: A powerful tool to protect against RSV 

According tο a recent systematic analysis focusing on children younger than…


Confidence in Childhood Vaccines

Declining confidence in childhood vaccines: A threat for today's kids.

"We cannot allow confidence in routine immunizations to become another victim…


Latest advancements in Multiple Myeloma Treatment

Multiple myeloma treatment: Why we still need novel scientific research.

Multiple myeloma (MM) is an incurable form of hematological cancer affecting…


CRISPR CAR-T cells

Coupling state-of-the-art technologies: CRISPR in the service of CAR-T immunotherapy

Cancer is the second leading cause of death worldwide. Many research and…


AAVs under threat

Are AAVs really under threat? 

Gene therapies can be the answer to treating, preventing, or curing various…


Viral and Non-Viral Gene Delivery Systems

Gene delivery systems explained. "Viral vs. Non-Viral Vectors Debate" 

Gene therapy is a medical approach that treats a disease by correcting the…


Biopharma CVC portfolios 2023

Do you want to gain insights into the CVC portfolios of 19 Biopharma Companies and Google? Then read below!

Over the past few years, corporate venture capital (CVC) companies backed by or…


Rare disease drug development challenges

How can we address challenges in rare disease drug development?

It is estimated that rare diseases affect more than 400 million people…


AAP updated guidelines for kids obesity

Updated Guidelines for Childhood Obesity - Are Drugs and Surgery Options Suitable for Kids?

On January 9th, 2023, the American Academy of Pediatrics (AAP) released new…


Expanding into Pharmerging markets

Thinking of expanding into pharmerging markets? Then read below!

As Benjamin Franklin said, "By failing to plan, you are preparing to fail".…


How Gene Therapy sponsors can overcome regulatory approval bottlenecks.

How Gene Therapy sponsors can overcome regulatory approval bottlenecks.

In a previous article, we discussed the findings of a Linkedin poll regarding…